Annual Cash & Cash Equivalents
$21.20 M
-$5.30 M-20.00%
December 31, 2023
Summary
- As of March 6, 2025, DSGN annual cash & cash equivalents is $21.20 million, with the most recent change of -$5.30 million (-20.00%) on December 31, 2023.
- During the last 3 years, DSGN annual cash & cash equivalents has risen by +$18.82 million (+791.13%).
- DSGN annual cash & cash equivalents is now -92.90% below its all-time high of $298.57 million, reached on December 31, 2021.
Performance
DSGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$30.33 M
-$15.37 M-33.64%
September 30, 2024
Summary
- As of March 6, 2025, DSGN quarterly cash and cash equivalents is $30.33 million, with the most recent change of -$15.37 million (-33.64%) on September 30, 2024.
- Over the past year, DSGN quarterly cash and cash equivalents has stayed the same.
- DSGN quarterly cash and cash equivalents is now -92.43% below its all-time high of $400.69 million, reached on March 31, 2021.
Performance
DSGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
DSGN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -20.0% | 0.0% |
| 3 y3 years | +791.1% | 0.0% |
| 5 y5 years | +10000.0% | 0.0% |
DSGN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -92.9% | at low | -89.8% | +43.1% |
| 5 y | 5-year | -92.9% | >+9999.0% | -92.4% | +1174.8% |
| alltime | all time | -92.9% | >+9999.0% | -92.4% | +1174.8% |
Design Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $30.33 M(-33.6%) |
| Jun 2024 | - | $45.70 M(+55.5%) |
| Mar 2024 | - | $29.40 M(+38.7%) |
| Dec 2023 | $21.20 M(-20.0%) | $21.20 M(-24.1%) |
| Sep 2023 | - | $27.94 M(+2.7%) |
| Jun 2023 | - | $27.20 M(-5.6%) |
| Mar 2023 | - | $28.81 M(+8.7%) |
| Dec 2022 | $26.50 M | $26.50 M(-37.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $42.52 M(-64.5%) |
| Jun 2022 | - | $119.65 M(-58.4%) |
| Mar 2022 | - | $287.31 M(-3.8%) |
| Dec 2021 | $298.57 M(>+9900.0%) | $298.57 M(-16.5%) |
| Sep 2021 | - | $357.66 M(-3.6%) |
| Jun 2021 | - | $370.84 M(-7.5%) |
| Mar 2021 | - | $400.69 M(>+9900.0%) |
| Dec 2020 | $2.38 M(+2989.6%) | $2.38 M |
| Dec 2019 | $77.00 K | - |
FAQ
- What is Design Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Design Therapeutics?
- What is Design Therapeutics annual cash & cash equivalents year-on-year change?
- What is Design Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Design Therapeutics?
- What is Design Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Design Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of DSGN is $21.20 M
What is the all time high annual cash & cash equivalents for Design Therapeutics?
Design Therapeutics all-time high annual cash & cash equivalents is $298.57 M
What is Design Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, DSGN annual cash & cash equivalents has changed by -$5.30 M (-20.00%)
What is Design Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of DSGN is $30.33 M
What is the all time high quarterly cash and cash equivalents for Design Therapeutics?
Design Therapeutics all-time high quarterly cash and cash equivalents is $400.69 M
What is Design Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, DSGN quarterly cash and cash equivalents has changed by $0.00 (0.00%)